Avantor Expands Manufacturing Network with Major Facility Upgrade in Poland
- Avantor expands its Gliwice facility in Poland, quadrupling capacity for USP purified water and WFI hydration solutions.
- The expansion strengthens Avantor's global manufacturing network, ensuring consistent supply of high-quality biopharmaceutical products.
- Avantor launches a new 60,000-square-foot Bridgewater Innovation Center in New Jersey to enhance research and development capabilities.
Avantor Enhances Global Manufacturing Network with Major Expansion in Poland
Avantor, Inc., a key player in the life sciences and advanced technology sectors, announces the completion of a significant expansion at its manufacturing facility in Gliwice, Poland. This enhancement is pivotal for the company, as it quadruples the facility’s capacity to manufacture, formulate, and fill United States Pharmacopoeia (USP) purified water and Water for Injection (WFI)-based hydration solutions. These products are essential for various biopharmaceutical applications, underscoring Avantor's commitment to meeting the increasing demand in the industry. Ger Brophy, PhD, the head of Avantor's Scientific Advisory Board, plans to present the details of this expansion at the upcoming Drug, Chemical & Associated Technologies Association (DCAT) Week 2025 in New York City, highlighting the strategic importance of this development.
The expansion reflects Avantor’s dedication to strengthening its global manufacturing network and ensuring a consistent supply of high-quality products. Benoit Gourdier, EVP of Avantor's Bioscience Production Segment, emphasizes that this enhancement positions the company as a trusted partner in therapy production. The investment in the Gliwice facility follows a series of strategic expansions, including a facility in Aurora, Ohio, which has increased the capacity for hydration solutions in North America, and a new production site in Phillipsburg, New Jersey, which has doubled the output of synthesized salts. These initiatives illustrate Avantor's proactive approach to scaling operations and meeting the evolving needs of its clients.
In addition to bolstering manufacturing capabilities, Avantor expands its research and innovation footprint with the launch of a new 60,000-square-foot Bridgewater Innovation Center in New Jersey. This facility significantly increases lab and pilot plant capacity, fostering collaboration and innovation across various bioprocessing stages. It supports upstream and downstream development, analytical testing, and viral vector research, thereby further addressing the needs of the biopharmaceutical industry as it continues to grow. Avantor’s investments in both manufacturing and research capabilities position the company to effectively support its partners and adapt to the changing landscape of life sciences.
Alongside the facility expansions, Avantor showcases its commitment to innovation in the bioprocessing sector. The new Bridgewater Innovation Center is designed to facilitate cutting-edge research and development, ensuring that Avantor remains at the forefront of industry advancements. Through these strategic investments, the company not only enhances its operational capacity but also strengthens its role as a vital contributor to the biopharmaceutical ecosystem.